BRKR - Earnings call transcript Q1 2019

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Hello, and welcome to the Bruker Corporation First Quarter 2019 Earnings Release Conference Call. [Operator Instructions] Please note, today's event is being recorded. I'd now like to turn the conference over to Pam Clark. Ms. Clark, please go ahead.

Pam Clark

you. Thank everyone. afternoon, Good welcome Bruker's to Earnings Quarter Conference Call. everyone like First to XXXX I'd Pam I'm Corporate Clark, Miroslava is name My and Director currently maternity Investor is Minkova, standing of Relations who and Development, on leave. our for in

Frank call and our Officer. on Financial President Herman, our are me and Laukien, Joining Chief today's CEO; Gerald

be Latest The In the we release conference section earnings addition this PDF Bruker website. today's a of be Investor the we'll referencing issued call, downloaded presentation on the can to Results slide earlier presentation. from today, Relations during

call, During website release our Reconciliations measures and to will are today's our financial on posted at we information. ir.bruker.com. highlight non-GAAP GAAP earnings are of financial included our in non-GAAP

statement, shown Before X. which Slide we I safe is like begin, on would to reference harbor Bruker's

in as today. XXXX. of not subsequent May the on not information, update following Therefore, to new of or today, with or release our course XXXX. and we'll X, SEC information but of results actual operational based we prior intend XXXX to, of early The and is today's forward-looking this be and on the are the the these website events risk the performance statements related representing results in August such as note future described those Also differ financial Consistent of from call, involves to making do uncertainties. outlook Form to discussed or views such prior not earnings that rely conference differences the release date current reasons as events regarding quarter include, statements to our business conditions our projections outlook materially might Factors in financial should second which may are limited company's and our our future the company on any on to XX-K, available other statements. forward-looking that our forward-looking website. and practice, statements cause that During our you in

the We the over business Frank quarter I'd XXXX call cover of Frank to providing for financials call will then turn detail. CEO, will Bruker's today's first a Laukien. the to more begin with like summary. Gerald in

Frank Laukien

Thanks, everyone, acceleration you call. for margin well another expansion as solid today's revenue delivered Bruker us afternoon, with joining on Pam. quarter and as improvements. and thank Good growth good EPS

quarter, first During we quarter the organic also and the was delivered gross In first year-over-year our growth of X.X%. XXXX, year-over-year margin again operating revenue expansion.

enabled our for impact fiscal our remainder with as pleased and are guidance results the acquisitions the in margin recent and XXXX. year of We XXXX with us of have confidence for raise operating combined well to non-GAAP for our EPS expected our non-GAAP outlook as outlook growth which revenue

Slide In an $XXX.X year-over-year Turning year-over-year, basis, increased the intercompany On to of at X.X% organic increased Scientific segment net specifics revenue X. now million. of first and Instruments revenue growth to X.X% a - increase eliminations. Bruker's revenue BEST, X.X% including revenue growth organic XXXX, on our quarter X.X% organic at

X.X%. growth, On year-over-year quarter, constant basis, year-over-year. translation headwind minus a foreign currency a added first the During was XX.X% to revenue currency of increased acquisitions revenue X.X% while

operational remained on compared single-digit markets quarter remained healthy Biopharma even $X.XX increased compared bit in softer growth translation. EPS. QX, non-GAAP organic & currency Bruker's as earnings share XXXX QX a XX.X% counting tailwind Industrial year - order as XXXX. Instruments for diluted favorable growth reported $X.XX GAAP per basis, year-over-year, in margin from in operating In were XXXX of bps with high not QX they QX 'XX which $X.XX profit of year-over-year, bps bookings EPS a some had trends the Scientific from bookings. is QX revenue the X.X had year-over-year, quarter to bookings government bps we non-GAAP the turn XXXX. groups, of operating share throughout foreign and margin FX academic to of been NMR gross Bruker of in to expected with in quite from our market XXXX as per QX first On of XXXX, order $X.XX Our X FX Order in of without higher minimal improved the first margin increased gigahertz the as In new while for microbiology XXX our with non-GAAP continuing revenues, FX XX of expected. Applied BioSpin XXXX, and QX, currency into XXX order last bookings well time. an improvements Overall,

turn periods. orders start. now, BioSpin performance and highlights Slide of and Instruments XXXX currency at flat BEST Group Scientific segment, on on Please all of currency $XXX X XXXX was QX our future the installations million I So a shifted some further QX constant and and X a where constant X good year-over-year groups into to provide as basis. revenue our

believe improved weak We is positioned organic quarter somewhat 'XX. in first XXXX the in continue despite to growth of for that the BioSpin start

spectrometry reported inorganic first group the digits double up organic microbiology quarter strong XXXX Our growth. was of strong contributed growth the with businesses, in majority to million. $XXX and driven the in by CALID to revenues in Bruker-Hain our acquisition Within CALID, and performance constant currency mass growth

Raman, on innovation IR, - to quarter middle trends] business by be first is track had molecular the Our expected applied Near completed our detection IR, healthy solid for for and Restructuring also products XXXX. markets. a by spectroscopy of from and driven XXXX [a product

the Slide and double-digit constant $XXX million less in one FTEs. we Bruker research the we academic remainder In and of acquisition and of factory April should materials JPK profitable Please semiconductor in advanced turn industrial for an to we mentioned first from and NANO NANO's nano reported results year, of results the driven before, mass the As X repair to in analysis by important expect i.e., governments currency products. revenue closed included about this Alicona. quarter had this demand reduction to contribute anticipate early now. in to contributions year. and XX x-ray primarily growth NANO that Germany NANO were in solid business, which quarter, XXXX. last acquisitions of results a RAVE XXXX, Anasys, also staff second result CALID

QX into was MRI currency BEST the digits in in up revenue in big for Finally, as strength XXXX in demand continued and mid-single constant the science pickup projects superconductor XXXX.

page, good stable world's I an the a novel pathobiology. will scientific high-resolution unique for announced from now high-temperature biology, XXXX, new early milestone this first showed low-temperature, combined very Turning intrinsically on it and a is key for important is at enabling a it importantly, an biology that had hybrid structural X. not first I magnet research This important disordered and we some in to this in read - an we everything superconducting In and is gigahertz Slide X.X update biology, milestones. milestone. molecular was show structural collaborators which tool, NMR quite it's ENC of magnet. technology the an has and this important because proteins dynamics April technology homogeneous but on is benefits was validation and, that a very number significant and early new scientific cell

for X.X some probe probe to some announcements is as other this we We very - significant that time applicable in membrane Europe, new from and the had Leibniz important solids enables are major NMR this a one in Institute they in has completely science. NMR, received temperatures, biological very And this probe play This order, gigahertz had at really that out pointed particularly that the also a or in protein allows to a also again are unique. disease role which ninth We do may signaling and aggregates. advantages, physiological sensitivity throughput probe Berlin. at it

updates the technical product or Project on Accelerate. other Turning to

on unique had very Association unique For HUPO proteomics which XD our sensitivity the It on flow really proteomics, news the provide quite a for tool. ultra-high a throughput we timsTOF EUPA at Pro meeting, progress with our is record-breaking tools, and our Proteomics proteomics. of X-dimensional, and really European bit U.S. XXXX,

gradually to timsTOF from And robust the i.e., even that days. think we $X,XXX dual We've much very, through into to all organic plasma proteomics. with suitable transforming unprecedented to and way. proteomics very unchanged: and on Project expect in sensitivity data clinical portfolio workflow in than which XXX timsTOF the than but sample of important. proteoms Technology excellence proteomics validation University and pharmacoproteomics new we phase X chasm, the and I cancer got the of the for eventually sustainable greater Pro margin here, be so dual driving uniquely $XXX really more XD next-generation this objectives single-cell X-dimensional capital proteomics NGS proteom lipidomics to get diagnostics X, to the and transition revenue as Award. proteomics a continue be is With go In this Returning businesses. On large for award, use XXXX will to very mobility perhaps completeness remain we EUPA expansion, almost That's will an some for to had X,XXX return unheard For via an the accelerate next where won't for ultra-high more terrific some approach capital. our strategy, details, Pro that It key scope rather Oxford years and growth to Bruker's it Accelerate with across high-throughput outlined on continue the maintaining XX% at samples be with to research multiyear important. also and as X research we perspective, cross-section disciplined to XXXX, the suitable amounts, the greater may We've important our of analogy summarized operational strategy while transition in got in our dimension of next small applications and research. business. metabolomics, customers speak, will provides or samples driving cohort, Slide coalition and our deployment expanded our on really proteomics that examples our invested of capabilities,

X.X% organic be acceleration, and a constant X.X% XX.X% basis. now continue guided we For a on further between to revenue X.X% XXXX, in growth currency between range to expect and or

EPS We by with non-GAAP operating margin $X.XX. are bps now year our of the non-GAAP we And year-over-year expect our XXX for guidance by to increasing guidance. expansion updated XX

we look with Day on our are June overall, you to our in we delivered So progress forward our updating York. far. how on on so Investor And New at our core XX very objective organization pleased has

over QX share the the year Gerald? our Let me XXXX. to now raised our Herman, our will who Gerald and for call CFO, XXXX guidance fiscal performance on financial review turn details

Gerald Herman

on you, $XXX.X up to X.X% That's XXXX, Thank million share from in a from you quarter XXXX. share. highlights, non-GAAP X.X%. which review per pleased of and organic $X.XX of starting first Slide On the revenue financial in share, XX. per QX today XXXX of quarter increased EPS Frank. reported join XX% $X.XX growth QX GAAP quarter Bruker's XXXX. I'm to reflects Bruker's of of $X.XX in reported XXXX We basis, an the XX.X% first per was EPS $X.XX increase first

XXX Our improved non-GAAP reflects This QX together XXXX operating margin favorable XX%, basis basis a increased leverage XX.X% income tailwind points of and XX mix, year-over-year. operating of with foreign while non-GAAP exchange points. volume improvement

decelerate operating be lower cover expect first guidance basis quarter free year and in the planned And tailwind expectations to XXXX the We margin expenditures. year our year-over-year in million to million in margin $X.X QX the further advances, cash increase approximately this expected of full compared to $XX.X with on capital reflecting of XXXX comments We shortly. foreign flow I'll on generated higher capital remainder XXXX working XXXX, foreign XXXX, full exchange exchange tailwind needs XX points. a in of cash my throughout

the timing to revenue unchanged and recent and of debt Overall, capital acquisitions, XXXX. QX course XXXX, in net XX, higher modest over quarter working versus were XX activity the for with our cash shipping dividends growth, purchases the we and bridge expenditures. ratio As acquisitions. the XXXX revenue revenue capital QX We we March working on inventory our position Slide capital QX a deployed was of as shows reflecting our of ended XXXX. balances,

growth positive Scientific the academic X.X%. and saw offset of revenue revenue of Alicona, contribution growth in markets. JPK As currency from organic was from foreign Anasys we primarily partially perspective, organic noted quarter a and From Hain, in by earlier, an headwind government a acquisitions, X.X%, X.X%. Instruments mid-single-digit growth our We acquisitions had revenue which was

our being see solutions continue and strong to We mass highlight markets, biopharma in applied growth the portfolio. biopharma spec with

revenue basis Our single a was Instrument Bruker's organically start, down up was Semi weak in microbiology XXXX. and growing digits. double high stronger, in albeit XXXX, American European revenue European from QX North business QX picked an interestingly QX revenues organic strong organic metrology is off on Scientific with were year-over-year, XXXX. to digits. Geographically comparison up orders a although

foreign well XXXX line with grew exchange growth, improvement non-GAAP QX basis Asia related QX and by as foreign as revenue XXXX by gross NANO Arxspan. organic as an driven and a tailwind. XXX margin XXXX from well from results. XX higher XX in exchange. XX.X% margin point QX China revenue growth Slide operating digits, XXXX of CALID expenses and QX in points in as to QX improvements double Pacific favorable versus Japan. on Alicona in basis This recent principally approximately non-GAAP expenses Non-GAAP increased operating roughly double-digit revenue of was XX.X% strong Groups up growth Hain, revenues profit our XXX including resulted higher impact acquisitions shows mix our our in and XXXX, driven and favorable points basis operational

the first effective quarter XXXX. XX.X% certain items. million, due compared XXXX, to were our first shares quarter average X.X up in from XX.X% non-GAAP QX of Weighted discrete shares XXXX, XXX.X was outstanding the rate million QX in tax For primarily to diluted

EPS non-GAAP of year-over-year margins. XX.X% higher driven by XXXX QX increased and revenue Finally, $X.XX

XX. XXXX timing decrease QX Slide was cash free the approximately in generated This driven the in of million to million capital increased year-over-year and by expenditures. cash QX in $XX.X planned We $X.X in to working Turning primarily advances, needs uptick capital flow XXXX. compared

X-day QX by DSO in XXXX. days DPO. consistent cash improvement the a driven Our backloaded was XXXX There cycle X-day XXX in in conversion offset end by a QX quarter, increase at with revenue our of of the was

up increase in revenue constant X%, up for Based the guidance XXXX on from are growth X%, of revenue X.X% by and expect XX.X%. and growth approximately to Bruker's now we X.X%, to results, We now for XXXX Slide our and of organic to upon raising XXXX to expected That to of recent equates Turning expansion revenue contribution margin X%. the X%. confidence year X.X% This XXXX full operating in a to revenue of XX. acquisitions X% to guidance now strong our impact includes X% outlook, from from our QX growth, acquisitions currency EPS. our

includes of well recently Finally, we foreign expect Revenue XXXX revenue compared from X%. XXXX X.X% in as acquisitions RAVE a and full original closed now approximately of currency year headwind our other acquisitions expectation to as as our of acquisitions. Arxspan

still that later class year. Our least at gigahertz assumes XXXX turns system outlook revenue X into this revenue

XX For XXXX from XXX to This guidance, XXX prior our XXXX margin assumed point of an compared full in which non-GAAP XXXX. operating we XX guidance XX now foreign to XX%, expect points our exchange to of Bruker's XX.X% basis XX.X% non-GAAP achieved operating basis year includes margin basis expectation level range brings to to expand to a points tailwind. the

XX%. year We continue to at about full our effective project rate XXXX tax non-GAAP

$X.XX. updated it XXXX foreign growth our all strong up, fully as are continue EPS a X.X% on to XXXX now XX.X% share solid in in our financial listed commitments delivered our call to early updating for in of organic representing slide to an with start like to performance QX in includes year. all from growth up. in XX% flow XXXX to our compared to Thank XXXX. session. of much. EPS And our and QX with the years, non-GAAP of to growth deliver XX% of Also, excellent most I'd other off to position of financial to posting half very XXXX We our XXXX, revenue the in This non-GAAP over expected To compared our QX year. the as accretion between to $X.XX, of We're a expectations that, on assumptions. on non-GAAP and Our be conference Bruker currency to expect and the you look $X.XX you range are profitability capital we quarterly call acquisitions. to August. second and XXXX progress Pam unchanged for are diluted turn the again the forward start Q&A is cash in count expenditures wrap and Adding EPS

Pam Clark

operator call the Thank like we're now to the Q&A [Operator Keith, to Thanks, turn to begin ready Gerald. the Instructions] over I'd begin you. portion. the to Q&A.

Operator

Jefferies. comes Brandon with And Couillard from the first question

Brandon Couillard

Frank, guidance the your given ever the early recall I year, quarter seasonally is can't Bruker raising year. which - in this lowest of it's

or order guidance was that And of the beat something in much rest book early year? business that year how right is this first and First, your Which raise in most in the improvement as that goes gives in you far relative go the you reflection a of the plan? the XQ of expectation to quarter? now our there to have segments visibility relative outperformed confidence ahead to the the as the expectations

Frank Laukien

did performance actually which consensus and little and mean we pass Brandon, our expectations, both. relative some then had own the of it's QX, want came a I relative we to thought. than out also to better to for on were it muted

that And of to order pass that not in weaker to year. so somehow imply gets the on some in later something we wanted

solid You know year. BSI most of really high-single-digit of bookings which, groups, good, quite second I said all the after X year all, again, earlier, And BSI patterns growth order order in last as to a organic in decent that start the was order argument. then were with

that, this with an step. was So felt we appropriate

have we at appropriate Although till adjusted this you're midyear right, waited anything, we time. but normally before seemed it

Brandon Couillard

on touch second. Then just for to a Europe

might in weaker you your orders? organic of be elaborate up be seeing macro the first You to little there? picture what inflection improve seemed despite of orders the quarter, you to which is on in And seemed terms top of Can end a sort view noted a there bit or markets an specifically, line.

Frank Laukien

I sustainable, not were a trends I there's any rates European high know growth new mean X.X years grand, and in Europe. year, don't came ago I they down. thought Yes. great,

As in year-over-year. you was our a revenue down gratifying. was have Europe a up bit. little heard, And in our QX organically That bit were orders actually

I - of kind or clearly of and traditional is just be think, - than patterns than therefore, perhaps lower So, to regions. tends which in thinking, my kind some into settling Europe its other growth

really of Now pursuing Accelerate so the within market our of is is And the than us drivers bigger Project we Europe, there deteriorates kind don't me, much - this the growth. also for strength our macro driving The product for point. which excuse trends third always at had macro innovation, macro, which we're are project are unless on dramatically, with we've - then it's not see mind. us, good areas

So a Europe settling I with quarter-to-quarter and lower-growth think environment into the more is noise. perhaps

Operator

And the next question Bank. Deutsche Leonard Dan with comes from

Daniel Leonard

over help make So understand first about milestone that you to expectations that the you of the us what the are following And achieving X.X tech reasonable NMR, How the field years? achievement? the X.X? backlog off, does Frank, significance the distribution have can gigahertz in ultra-high of for feel

Frank Laukien

Yes.

So first X.X important us using gigahertz. milestone, to that that insert, gigahertz we it gigahertz allow if ship for will revenue X.X the system also hybrid the the superconductor presumably goes be year in It insert, was year, you well. an technology same with X.X is the next should for as everything magnet high-temperature realize. HTS later

same the important while X.X it is towards technology. And uses so X.X milestone gigahertz, the an gigahertz

also bit gets harder quadratically magnets. check, quite So harder you sort in But for good. of everything just and not that's harder XX% because a - it's

this - business we our more remains still every sometimes this do to reach, in factory be with hopefully, gigahertz, more. a but and quarter, year seen. milestone not to work you X.X setback but also later that costs at important And to have So milestones

X.X yet. with So there I milestone, better but feel much now not it's - the we're gigahertz

Daniel Leonard

Appreciate color. my And follow-up. then that

much double-digit versus new On consumables long on growth. placements is a ago? microbiology you some growth the versus instruments mentioned you you how that installed maybe cycle elaborate Can replacement time of business,

Frank Laukien

It's been healthy all around.

have very significant assays, in with So a beginning units all little new business There not yet. good. the but been replacement that Biotyper also as nice expected, it consumables growth It's for placements really yet. much bit, is but isn't new

but So some - mostly, just a second and little maybe one so labs it's much get still or a so. replacement placements not new bit

replacement cycle, big new were placements and were healthy, consumables a not yet So healthy.

It also So pretty the around. pretty it really decent. good was solid, all was and were various all quite geographies

Operator

from comes and Lin, And the Cowen next Company. question Chris

Chris Lin

on This Doug for Chris is today.

the the solid So like been are out revenue. capital and data. past That on China of strong a to job a there corner called year China growth have it looks converting mixed order And your said, you some you doing turning the peers called macro has weakness. over out few

a change you're China in to with could meaningful there that order detail has And more environment? the provide just mind, been demand trends? So seeing what on in you bit

Gerald Herman

that. Gerald. I'll It's take

So generally revenue solid you're the speaking, right, in China had quarter. first in we very growth

from for China full well. But the year XXXX a at in think I quite growth guess significantly performed what less We're a I growth anything as variety rates not impacted reasons. China. Tariffs have would have with well revenue order be - would I we see us there thankfully, of say, entire unusual expecting tools seeing we're our really for We growth line would more industry perspective. I not in I or to say

Chris Lin

Frank, you commentary you such seeing scimaX? just on to spec product franchise you very And products, And perform do the share? some provide of are Okay. your taking I And as guess are could some then and then mass timsTOF where demand? well. newer think you what the strongest lines continues

Frank Laukien

lot making progress solutions, for biopharma to label-free discovery. Yes. drug our at they launched glycosylation a screening rapifleX good in imaging other patterns that were timsTOF based or ultra-high maXis base, proteins. but can which were PharmaPulse, the industry, does doing changes we not have proteins intact year They're solutions - MALDI the in of base, also were the can well not with are on MALDI other be well-performing There mass biopharma be or last variety intact - a of in forget looking all spectrometry-based which throughput, good for products making based,

no timsTOF story. broad timsTOF making Pro is progress by just So we're good the it means it's pretty with but based, a Pro, and

solutions good biopharma a also then I particularly some but into applications of innovation for discovery. drug - or problem think workflow and useful turning products for small-molecule application's for had these in given we've product also

relatively been products broad you well. also based, it's are and mentioned So performing the

Operator

the Unger question Needham with comes next And from & Steve Company.

Stephen Scott Unger

up lines success to China - product you China? Frank, on seeing what just you color could are the could on in provide little follow maybe a question, more

Frank Laukien

Yes. I this had growth mean we we that if in recall, revenue China. trend, weird Steve, bookings not and excellent had you growth much year last

Of China such good a And year. now bookings relatively China. Because think observed then broad Certainly, very course, orders think that as had we've kept year little a elsewhere - in slower and yet of growth based, full on a that QX in uptick, mean in not we've to of good hopefully, doesn't or, in the leading industry, because eye pickup for bookings sustainable is last our the and a we sustainable very in year. revenue - that anything uptick the in example. looks the was strong increase last discussions QX an a in pipeline BioSpin plus good I China But was well. some I

it. really that So very much I don't know into I read can

BEST We happened yet expect but extent. significant least either China a that of or to at it not orders to maybe in hasn't lose some tariffs, because

answer not the quarter quarter for a is is So statistic. a as - lame and a just us

- don't patterns cannot I right and - So Bruker perspective now from discern for a any real China. I

to I a From a the together start quarter, it's and had good think for I early stitch cannot this one year. year, too trend. decent have we'll say. there We just growth

Operator

with And next from the Souda comes SVB question Leerink. Puneet

Puneet Souda

sense X.X maybe I up you Europe. Europe. just of one X get a to gigahertz So in first - on here just have of following wanted orders

sense to delivered the first. sort so environment wanted just couple seems over in are thinking in And Europe going any there's systems like of of of these how so it's outlook the challenges funding next us about a just be gigahertz of long-term get if a to you mind, with years, over there I give the - and sense terms X.X of because just

Frank Laukien

Yes.

X.X when that trends I it's the positive excluded all, - QX order from European Berlin. mentioned could slightly again of got one the being year-over-year, distort because the first So these picture, we I in earlier gigahertz

for take it'll year. I years. definitely we'll And And comment, year the going to backlog one over then don't us because X like all won't a X ship quite Asia. this a replenish ship honestly, which we is yet couple that somewhat of next Second That's sure. might not to or would imply more in - in of or know X-year and to X the am if they optimistic This or years, - that going more we're even pipeline both X that years. X ship Europe in we in whether couple there's next something story.

that U.S. least, backlog think So the you've U.S. gets how organized. NMR U.S. when don't getting And we'll not but ultra-high in field as done. that ENC, now later. I funding, But heard, simply and work the good be off happens in something sooner will is and organized, we goes. last And applying at Puneet, there's see usually some the interest for heightened or

assumption. know first will one work late be. will If on we on can if the year. makes accelerate gigahertz don't great, but that, thinking X will yield to - everyone not a the perhaps that - story, yet be starting a XXXX that, that field X-year about so. the like just what ramp try, X.X helps know So but first don't not a times [just] the in this just it as X-year or delivery may more be It's It's that better you, even it's we these

So and that's you all yes. wanted more detail the to than hear on that probably,

Puneet Souda

that or of just remind this metrics view have installed give could terms product elaborate where you in seen metric you in us this go this the could that - is customers' any detail. category product. timsTOF, with us a any product in of this in of No. there? you hand And experience And of and that Can in is I this you this the provide base? more Obviously, growth can where appreciate you some your had stand and this you and terms expander - the installed on sort point? - at base

Frank Laukien

a Yes. yet. category It's not expander

still have very now additional usually deploy signs although clinical to early buy LDTs are and systems right them, some instance, eventually. some people explore the days. leaders early think I get they're already systems this proteomic might that opinion there But well-known that those proteomics various validation to key for that's or proteomics clinical of labs, other some really

that think this as we we expand category, if will the proteomics the today. the beyond I market, it research So eventually growing market interpret proteomics have

So over time, that. it do may well

now received too right is complementary bit out as and are but it is is an there. certain proteomics a that early, additional set that to other it's a capability tool little that unique think tools with I well

can quality So installed is, with good we're that And course, on product or we're line. early point want a think ASMS, do of the so acceptance. science. - up pleased good finding job gradual soon. at commenting adopters that it is unit we is of finding we of that the bit which see they a do coming publish to I that quite ramp-up numbers, at with have And you'll base but this it most not We're importantly,

Operator

question Tycho next comes our with And Peterson JPMorgan. from

Tycho Peterson

Biotyper. with starting maybe Frank,

improved want] throughput, series [you Sepsityper think the well. whole as a during of had library the and You quarter, expansion, I announcements

time curious could Just and adding AST? these things any think accelerate placement you how around lines

Frank Laukien

just yes, incremental year, more improvements Every Good But diagnostics, so everything and onto in content put questions, on not I'd solid same add is the things more Biotyper platform. were they the Tycho. you and platform. add MALDI Yes, - and revolutionary. so say

we're that ASM the world. at U.S. for also MALDI given consumables further systems in stream our end year. more identification capabilities, pretty announcements in the that platform think Microbiology, in assays a in have holding, for least additional yes, in possibly of certainly this We the that and have and and American market we Europe also share unique June, out. elsewhere ASM, expect San more very at Society And Francisco at expanding, coming we and are healthy We

us. some at excellent won't that very mix - systems healthy just It look and well explode, this I If the growth fast low good for of anymore. And very grow as looks has - consumables, business. quite overall, that this double-digit So aftermarket a be we a could is may for margins I solution but area if be time. this I not think partners. like a But could have very

BD have pleasure them, and partners Beckman that a work they're part a of and to are strategic as a bigger well. We Coulter, with big it's that and couple of companies, success

Tycho Peterson

the Okay. of only then broader $XX And light small, million we you And the then you a growth just rationale about and semiconductor know the could I relatively to question market But RAVE are in curious onboard? cycle, on talk in that if the just the process profile revenues. it's can of if in of where talk business. acquisition. putting thought

Frank Laukien

isn't and of is it? anticyclical of half recovery Yes. It's We're a for Semicon move second in the little a as that. people the weak, by year. there, still bit impacted an some hope not

already. First of weak around less RAVE maybe to than all, semi is year X%, of prior It last total X%, only our revenue. was about

up remains elsewhere. with or catch on this The Journal weaker that we weakness Street year's Wall read can the side, not us. it's it so will all far, in But as So

and that semiconductor technology. spend think to a masks valuable And mask you is those those, that - incredibly clean cycles. you're to are nice really easy industry. RAVE customers. we will have not going be those vulnerable today in so they the repair calculation an cleaning That's investment. for tools, Actually, to that even economic or more So when Their

uses perfectly call a that very points well-known technologies. so like customers. different synergies some service, So with our addition. and very semicon it there well in and marketing It we into customers and same nice the atomic call on some are distribution big slightly is but It thought intermediate-sized it was range. We not microscopy, good similar force fits

couple a just maybe year of correctly, well of So year technology it was call they how question perform remainder the this the looking now nice really years, for cannot us will in very be. growth. had in their - And But next your acquisition. the last - nice interpreting This I year. should business

of So a and should good have they're it growth margins. this good a year, trajectory, so be in should and a remainder have - good they they

Tycho Peterson

And before off, hop just one Okay. then clarification. I

the Europe? pushing in do an of of Are beyond far outside think the over course could see your Or you book you time line been what's suggesting U.S. in gigahertz, On the X.X has the order maybe order year? we Europe, Europe. so the all

Frank Laukien

and is orders out countries can't a money 'XX. think going I expect gets the it's bet together on My in probably coming year. would could I into very the to - wish knew. this be non-European but I APAC, that more It them would coming, occur. rule that maybe I be it's difficult but that in then it's 'XX more they're first may I next possible without order would someone right now, year, if say. U.S., to And

Operator

with the Jack comes And Meehan next from Barclays. question

Jack Meehan

of compare dynamic walk when operating to the I guidance how How margin started that quarter. Gerald, the year? into could relative the through line the that the guidance? margin on you to me benefit terms of we much hoping is FX coming quarter, contributing the operating prior to And the in in did was your raise

Gerald Herman

Jack. Sure,

way probably on the you line. percentage It this to works margin revenue relative the a helps as know, generally the hurts is us operating on dollar stronger euro the us generally speaking, So line. U.S.

case in first So at on - EPS we're - line, exchange much first guidance for as have quarter. didn't a for got it you actually the foreign heard, on the because revenue actually overall impact a And quarter. happens assumed from it's our impacting side. significantly we actually not here, operating big It's a probably margin the exchange X.X% margin foreign in really headwind operating it's our the revenue tailwind what projecting we've perspective

to points decelerate to year. of that basis XX over expect we're about operating tailwind on the rest And the the actually We be margin line. that expecting

view elements, relative sort quarter. I revised of went revenue exchange our after our the foreign first the that's So in on to in guess activity say. performance the We would I first we saw quarter that

Frank Laukien

the operating less call it at we since we out initially FX maybe it in expected to level. we tailwinds. it call gave more. And the to overall But was XX, it felt significant XX didn't become QX, it be a to and, year appropriate February bps for margin It's therefore, expected bit on profit guidance out. we some when And expand, little for more the year full

more - bit, went modest our - specifically. little there in up into question tailwind always also that a - initial So modest it was and was guidance, but very some baked your to answer

Jack Meehan

hoping Nano I just great families all performance maybe, performance in was And the Frank, and you the was some a how by through Can on that. That's positively little quarter. product what of and surprised Yes. color. color just us I walk organic there the bit more give then the - was?

Frank Laukien

had revenue not for they than microscope. and comparison and a Nano Yes. year-over-year call was because AXS was Surfaces out, we still certainly QX some QX growth out strong given we did also they very their - QX after as picking 'XX. had they actually but that's a fully I bit okay. also little some expecting well, XXXX. a pushouts but semi into the No, last had didn't they're slower QX, QX. expected QX one mean that lines B also and doing B some next-generation that And bookings weak product the of strong some small of And it That's in called Nano had fluorescence like had product it we up introductions really science quite line, had very, bad, life with think from Bio. product yes, in well I

be - to say So was weak new that comparison. that's I wouldn't just happened It a a trend.

pieces are those together. the come that bits So and

yes, good good some and double-digit mix. benefited Nano inorganic growth it's the from have that business. the growth, growth acquisitions that even A So, although included

Operator

Evercore. next the Ross from question And comes Muken with

Luke Sergott

It's Luke on for Ross today.

sheet. one balance on the of kind cleanup Just

today. ordinary anything the there working is had the guys You a out with that? that pretty big Is of cap in step-up

Gerald Herman

a of we I our buildup on mean revenue later growth inventory working little bit our of an the function in extent. the our up in to wouldn't revenue have higher. largely Remember going of And and say but I helped so. No. increase some had those, a bit timing as we DSO, that build balances quite acquisition a also a we have of are Gerald. activity did that's bit quarter. activity some capital to little that It's well and

not seeing we're unusual anything So really. there

Luke Sergott

And On that, that Okay. then major do you little you how like on the Kind what of kind $XXX, of then something the ultimately to to what - where to timsTOF. instrument from get do you do disruption? disrupted. over? you about the going see more Fair. I'd taking see talk bringing down is opportunity? $X,XXX When proteomic touch And ultimately, bit size a

Frank Laukien

been next-generation chasm to disease and terms quite spectrometry, little proteomics possible - has towards going mass sequencing. we're informative And cohort that, to and that a very at very decade and for not pharmaco good I take much the I actually towards the good broadening think really to robust, And proteomics, That's least proteomics of and not a clinically clinical in think for and which be that's should at Well, beginning gradually. science proteomics the behind disruption. a old category, that's and technology overall. Proteomics be large begin be just may that be could I least much a yet, that of healthy the with question. validation, it's been I as think has where reproducible market may the crossing there never it that new just think by trials as area. depending more drugs on there. the it's wasn't perhaps getting technologically, becomes But off

lagging but catching think trends or a And NGS of may so ago I decade what happened just and so are with behind now. you that - see up some reminiscent in

that urgently technologically, timsTOF I the Pro needed, and - these to inflection do studies these that point. can proteomics to fields think And it's where it at to that think I reasonable But reproducibility. expand contributing good robustness possible hasn't been cost information. really is with larger-scale

Operator

next comes De Bruin Lynch. from America the question Merrill And of Derik with Bank

Michael Ryskin

part on something discussion with And on little something Or give your for quarter. this Mike is bookings the is Apologies Want magnitude Q&A. going of Is of industrial Could little color Ryskin there that? just during more missed you there Europe? out to bit I Derik. on on? in on else up follow mentioned from overlap the sort if softer break a the you there. there This something think another But about I being earlier. a

Frank Laukien

like had little really Yes. bit it's markets think long We after were exceptionally been and I comment. a just mean last malaise similar a year. there's - - a Industrial healthy bookings I industrial

And so longer-term sustainable had we - a of going sort bit think a level. little more as to think a of to there's we be settling expected, we

on the level. its of industrial boom that's - we're on yet. seeing hopefully, unsustainably that, single a to side, we seen wonderful like we're going a a sustainable so not more, bust previously down we've of Europe bit seen digits, here. bookings, it it to haven't maybe We the have bit a from high ago We're when research little made sustainable. probably from coming But to comments can't. not little going coming them more Europe I And last. year a was that bookings levels about said don't out think And It's - but a revenue becoming down that to and that's I growing the longer-term in may course, seeing

growth. other that very good by fields had surrounded obviously, there, comment the that's So

for So weaker unexpected industrial, mind last semi already. was in not that's year keep that And within us.

is So the it's it bookings. going recovered hasn't down - year-over-year yet, comparison really not in but year-over-year also

Michael Ryskin

that very actually, rate follow-up it's been quick deal a long over mean very, steady a the a run I appreciate color I time. Great. And pipeline, very on Frank. And then

a down in remarks for there. It the the capital like sheet going comments of terms and should modest same? the the there more really in of think we mentioned balance expect rest the Or change some But in a we should You outlook the up. prepared on about seems of deployment the year road? the tick anything leverage is

Frank Laukien

acquisitions and acquisitions X deal, this tiny X.X so asset did far we So X so year.

suspect X be looking you'll of think the for I early at RAVE or then We next - pace expect not be We we had well amount strategy pipeline possibly. even that trying company. deal in of additional will this opportunities closed fit that because last X then But our with QX I M&A quarters year an into into unusual deal slower. year will deal acquisitive unusually deal less of high an be do the flow not to for our smaller our We're had We're in to I spending quarters. And had early flow. April. least, year that previous April the see, than and suspect just couple of we this QX

that's not that's strategic or available. coincidence planned. of somewhat come yes, the - That's So how become and things along

of M&A So next quarters. my less prediction spending couple is for little a the

Operator

And the next question with from comes Dan Brennan UBS.

Dan Brennan

Project call, quarter. know can talked you've but the high implicit of specific of Congrats already kind you kind represented that on category again? the of backlog Frank, about revenues and in on for like level what of products? products talk XXXX kind total those kind by of on I Accelerate what's just update on percent the growth a products you lot now? Can of just us of

Frank Laukien

Yes.

or at the more year on some that give breakouts of detailed - in average, only a So it the end we year. had working what do in that can tell was corporate of Project of of once more now, detailed the fact the you it's that in the and - than corporate growth again average, growth QX mean color, I directionally higher terms Accelerate organic that we was we give digits. And double percentage revenue the I higher in that is that Project Accelerate the than

So we for just that 'XX. did

we very But track. 'XX, to the really be end the on working. And to again strategy expect seemed so formula on update of - revenue percentage you give And and of it's what nicely. is. the working our an we'll at It's

'XX keep I quarter's arrays, X.X didn't answered map and that the provided that we in road that there part, Tycho had that this previously aren't AST, include what be mind, slide, to syndromic - liquid doesn't, going things, in are we year and about what part kicks Now asked never of this some that of i.e., panels, story. in gigahertz, earlier

This come expect out microscopy so gigahertz and X.X don't them proteomics in 'XX with business. our some until we more And of growth even fluorescence year on. and in

come a this So additional difference in 'XX 'XX. kicking last drivers that also of things won't that but much year make year till or didn't that's

it again, map applies we applicable. So and year still to And working. we that is good the about much seems road that really be feel distributed still in and very it, previously early had

Dan Brennan

year the the what's it I you full on happened assumed And know said of of then Okay. kind you just elaborate on flat what mentioned and quarter, was and of for growth? organic Can you BioSpin slipped. in in terms BioSpin, things some kind

Frank Laukien

Yes.

growth it BioSpin, we as and Nano our the organic actually the mid-single year CALID as expect so full in groups. by similar have rates guidance digits or implied For to

It's in orders wasn't that But not really it wasn't will apparent they and just that slips delayed. did get but that a was lame QX, in Now technical more some apparent excuse. year. that wasn't last come

get - issues March. installation preclinical And in that made we it impossible and a just to some areas on systems other had them couple some of into certain

they'll So probably QX. come in QX or

expect have BSI other any for a comparable So software, X but are that's It acquisitions small it growth There digits rate an the have doesn't actually to groups. year, rate. in - similar the only we growth to organic mid-single organic the in growth acquisitions.

B up So to Bio quarters. in the expect step subsequent we

Dan Brennan

one And then one. maybe last

key even of And are things you've you orders? in already. Is But areas? in that have sustainable? naturally just so, better I due And in the asked had than anticipated? of they cushion guided. what are think than had a you've the the to might baked Or coming been terms last you in that and of you it quarters, seen couple internally better come if kind those

Frank Laukien

out building what more where we gain we could we QX nicely a terms in sticks to as executed up singular And confidence. to yes, just revenue. Nothing relative event. well more of in It's execute gradually

- buildup. be it's and hopefully, another part a quarter steady will So

Operator

from Instructions] with Sachs. then Patrick [Operator question Goldman Donnelly And next comes

Patrick Donnelly

on are actually region? saw through how volatile, just guys. for you to Japan Asia the you Can little China there? that Pac. a a notable Maybe but but about performance tends one pretty it headlines, what know grabs you be feeling guys always you talk was just bit I

Frank Laukien

was that. growth pleased a that QX. good sustainable, at level strong We're QX quite Japan more is It with that's but it volatile. in was not Yes.

You also know or that from most their runs differently the year fiscal U.S. for countries. European

pleased good, so but and with we're yes, Japan that. And - was

there some our of over science science a and industrial companies. well and just as in of of as of the but are industrial does research life life some pharma research good pharma tools research tools tools. a lot And good academia traction Japan lot getting

in areas, I number generally research. capability, point for the or available So out those Japan, of or in business tools was would And a are tool. life just they well believe And that cases do many we have believe In stress a the in Japan. I science also. for industrial things they I when the best Japan need certain and either uniquely even really enabling doing microbiology in look

I that. strong - yes. good, the no, be been acknowledge It a has had year. QX. for Japan good pretty of won't So And that it remainder the

Patrick Donnelly

since been a few years it's next one. maybe held then guys you Analyst month, And the Okay. just coming with up Day

I the think like it last things margins, time improving on cetera. was attach rate, the et focused service

planning what guys bit to on as should out agenda As you're here, of you a focus expect the a teaser? we really

Frank Laukien

steady to Accelerate innovation be and quite and could talk, markets there. course, you we sizes years initiatives X expected is we'll pervasive also excellence maybe commercial therefore, of everything to and and excellence the we medium-term to this roles so the in about do, as Project Well, market We, of these also for addressable give and XXXX. about intend operational talk how our theme beyond and not much, evolve maybe try outlook, next markets product or how play what

And so teaser. that's the tantalizing

Operator

Willoughby Research. the And question Cleveland next Steve from comes with

Joshua Waldman

Steve. Appreciate It's for squeezing in. Josh on you me

software seen one a buys you. Just a do recently. the quick couple company Obviously, for of

if and you kind near- opportunities about with could deals. Just wonder these of talk longer-term the you see

Frank Laukien

Josh. Yes,

that's for our I more chemistry, in deliberately year, QX, us. doing accounts. of Arxspan where of quite Yes, But scientific consciously course, beginnings. picked for in industrial have yet. software in provide will we're they - important your and one with they position in I up Analyst took the being and to for small capabilities on eventually QX software of small, both not stand-alone some - majority You XXXX, mean biopharma this Day some on the academia pharma fields more and we saw adding in strategically that's it's in more report. in industry, They that X and But this know a software, and that. Maybe acquired think I much we either that they're focused being I last capabilities Mestrelab, focused synergies. be

it is they're benefits the that's small our pretty although fit yes, good So together. a beginnings, hopefully, we're and that one of a as smart areas And strategically rest driving way for more well. us, of deliberately the in business and,

Operator

over other And closing would as I there are no for like questions, comments. Clark to Pam turn any the call to

Pam Clark

you for us Thank Yes. joining today.

will the Healthcare in in Jefferies quarter, second Boston and During the Bank Conference participate New Deutsche Bruker Healthcare in the York. Conference

Investor at you to forward look also seeing in New Day XX. We on our June York

our we to Thank let Massachusetts. of a invitation, course, visit please us headquarters you, at evening.\ you If an in invite received Billerica, haven't you good have and know. And us

Operator

is you. you conference Thank today's Thank now for concluded. presentation. attending The

your disconnect now may lines. You

Pam Clark	Investor Relations
Frank Laukien	President and Chief Executive Officer
Gerald Herman	Chief Financial Officer
Brandon Couillard	Jefferies LLC
Chris Lin	Cowen and Company, LLC
Daniel Brennan	UBS Investment Bank
Daniel Leonard	Deutsche Bank AG
Jack Meehan	Barclays Bank PLC
Luke Sergott	Evercore ISI Institutional Equities
Michael Ryskin	BofA Merrill Lynch
Patrick Donnelly	Goldman Sachs Group Inc.
Puneet Souda	SVB Leerink LLC
Stephen Unger	Needham & Company
Tycho Peterson	JP Morgan Chase & Co

Bruker (BRKR) 6 May 192019 Q1 Earnings call transcript